MedTrace Logo

Quality of Life Study Breakthrough Cancer Pain Treated in Medical Oncology Services (CAVIDIOM)

NCT03435120 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 118

Last updated 2020-03-02

No results posted yet for this study

Summary

In cancer patients, pain is one of the most common symptoms. The range of reported prevalence of pain varies from 33% to 64% including different stages of cancer, during or after anticancer treatment. Moreover, despite the optimal management of basal chronic pain, 66% of these patients have reported breakthrough pain which has a severe impact on quality of life. There is insufficient clinical information on the quality of life of cancer patients with breakthrough pain treated in medical oncology services according to routine clinical practice. For this reason we consider it is appropriate to prospectively evaluate the quality of life of cancer patients with cancer breakthrough pain in medical oncology services as well as other factors that can affect quality of life. This post-authorization observational study will assess the quality of life of cancer patients with breakthrough cancer pain treated in medical oncology services in Spanish hospitals.

Conditions

  • Breakthrough Pain

Interventions

OTHER

No intervention

No intervention

Sponsors & Collaborators

  • Apices Soluciones S.L.

    collaborator INDUSTRY

  • Angelini Farmacéutica

    lead INDUSTRY

Principal Investigators

  • Carlos Camps Herrero · Hospital General Universitario de Valencia

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-21
Primary Completion
2020-01-24
Completion
2020-02-14

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03435120 on ClinicalTrials.gov